A. V. Markin
A. V. Markin has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana R. Tomenko
Ural State Medical University, Ministry of Health of Russia
3 shared publications Маркин А. В.
ООО «Институт детской и взрослой неврологии и эпилепсии им. Святителя Луки
2 shared publications- A. V. Yatsenko
EpiJay Clinic of Neurology and Epileptology
1 shared publication - D. D. Korostovtsev
Clinic of Neurology and Epileptology “Epidzhey
1 shared publication - E. Sh. Sagutdinova
“European Medical Center “UMMC-Health” LLC
1 shared publication - Elena Dmitrievna Belousova
Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University
1 shared publication
Latest Publications
- Open Access
- 30 July 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (2) , 80-96
Epilepsy in patients with Down syndrome (literature review and clinical cases)
An overview of the literature and clinical cases of epilepsy in Down syndrome (DS) is presented. Epilepsy in DS has a bimodal distribution with two peaks: before 5 years of age and after 40 years. In childhood, the most common epileptic syndrome is infantile epileptic spasms syndrome. First-line treatment includes vigabatrin and corticosteroids. The second peak of epilepsy occurs after the age of 40 and is associated with the coexistence of epilepsy and Alzheimer’s disease, which is known as late-onset myoclonic epilepsy in DS, the seizure semiology of which is similar to that of juvenile myoclonic epilepsy. Clinical cases of patients with infantile epileptic spasms syndrome and DS successfully treated with vigabatrin are presented. Comorbidities in DS include a high prevalence of obstructive sleep apnea syndrome, increased carbonic anhydrase type 2 activity, and the presence of myoclonic seizures similar to those in juvenile myoclonic epilepsy. These features support the use of sultiame as a pathogenetically justified drug for the treatment of epilepsy in patients with AD. A clinical case of a patient with DS is presented, in whom sultiame demonstrated high efficacy and good tolerability, as well as a positive impact on development and behavior
- 30 July 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (2) , 80-96
Open AccessEpilepsy in patients with Down syndrome (literature review and clinical cases)
An overview of the literature and clinical cases of epilepsy in Down syndrome (DS) is presented. Epilepsy in DS has a bimodal distribution with two peaks: before 5 years of age and after 40 years. In childhood, the most common epileptic syndrome is infantile epileptic spasms syndrome. First-line treatment includes vigabatrin and corticosteroids. The second peak of epilepsy occurs after the age of 40 and is associated with the coexistence of epilepsy and Alzheimer’s disease, which is known as late-onset myoclonic epilepsy in DS, the seizure semiology of which is similar to that of juvenile myoclonic epilepsy. Clinical cases of patients with infantile epileptic spasms syndrome and DS successfully treated with vigabatrin are presented. Comorbidities in DS include a high prevalence of obstructive sleep apnea syndrome, increased carbonic anhydrase type 2 activity, and the presence of myoclonic seizures similar to those in juvenile myoclonic epilepsy. These features support the use of sultiame as a pathogenetically justified drug for the treatment of epilepsy in patients with AD. A clinical case of a patient with DS is presented, in whom sultiame demonstrated high efficacy and good tolerability, as well as a positive impact on development and behavior
- Open Access
- 30 July 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (2) , 46-58
Epilepsy in cerebral palsy: problems of antiepileptic therapy
Epilepsy and cerebral palsy (CP) are among the most frequently co-occurring neurological disorders and are characterized by high comorbidity. This article provides a brief overview of the issue and presents clinical cases of patients with CP combined with focal epilepsy of childhood with structural brain changes and benign epileptiform discharges of childhood on electroencephalogram (FECSBC-BEDC) and infantile epileptic spasms syndrome. Vigabatrin is a first-line drug for the treatment of infantile epileptic spasms syndrome and can also be successfully used for focal epilepsy in patients with CP. Due to its GABA-mediated mechanism of action, vigabatrin has demonstrated the ability to reduce symptoms of spasticity in dystonia. Although the FECSBC-BEDC syndrome has been described in patients with CP, it has not yet been assigned a taxonomic position in the International Classification of Epilepsies and Epileptic Syndromes. Sulthiame has demonstrated efficacy and good tolerability in patients with FECSBC-BEDC.
- 30 July 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (2) , 46-58
Open AccessEpilepsy in cerebral palsy: problems of antiepileptic therapy
Epilepsy and cerebral palsy (CP) are among the most frequently co-occurring neurological disorders and are characterized by high comorbidity. This article provides a brief overview of the issue and presents clinical cases of patients with CP combined with focal epilepsy of childhood with structural brain changes and benign epileptiform discharges of childhood on electroencephalogram (FECSBC-BEDC) and infantile epileptic spasms syndrome. Vigabatrin is a first-line drug for the treatment of infantile epileptic spasms syndrome and can also be successfully used for focal epilepsy in patients with CP. Due to its GABA-mediated mechanism of action, vigabatrin has demonstrated the ability to reduce symptoms of spasticity in dystonia. Although the FECSBC-BEDC syndrome has been described in patients with CP, it has not yet been assigned a taxonomic position in the International Classification of Epilepsies and Epileptic Syndromes. Sulthiame has demonstrated efficacy and good tolerability in patients with FECSBC-BEDC.
- Open Access
- 30 April 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (1)
Threshold analysis of the patient’s route in infantile epileptic spasms syndrome: from the onset of spasms to first-line therapy
Background. Infantile epileptic spasms syndrome (IESS) is one of the most severe forms of early-onset epileptic encephalopathies and is associated with a high risk of pharmacoresistance, severe cognitive impairment, and premature mortality. Disease prognosis critically depends on the timeliness and adequacy of first-line therapy. Although delayed treatment of IESS is a universal problem, the specific stages of the patient care pathway at which delays occur may vary substantially depending on the organization of healthcare delivery. Aim. To identify key threshold stages of the patient care pathway and major barriers to timely initiation of rational therapy in children with IESS within the healthcare system of Saint Petersburg. Materials and methods. A retrospective observational study was conducted using the archive of the Epilepsy Clinic since 2018. A total of 130 children diagnosed with IESS according to International League Against Epilepsy criteria were included. Clinical and anamnestic data, magnetic resonance imaging findings, electroencephalography/video-electroencephalography monitoring results, and genetic testing data were analyzed. A threshold analysis of six consecutive stages of the patient care pathway was performed, from initial recognition of spasms to prescription of appropriate first-line therapy regimens. Early treatment response was assessed 2 weeks after therapy initiation Results. Developmental abnormalities prior to epileptic spasms onset were identified in 78 % of children; potentially epileptogenic magnetic resonance imaging abnormalities were found in 67 %. Causative genetic variants were detected in 18 % of the entire cohort. In 39 % of patients, the diagnosis was not established within the first month after spasm onset. In 96 (74 %) of 130 children, rational therapy was initiated more than one month after spasm onset. Six threshold points of potential treatment delay were identified. The main point of patient loss was late recognition of spasms at the stage of initial medical contact (loss of 27 out of 130 children). Moreover, delay at this stage deprived the child of any chance to receive timely therapy and constituted an insurmountable barrier to the subsequent steps of care. The second most important barrier was failure to initiate appropriate first-line therapy at treatment onset. The effectiveness of first-line therapy was more than 12-fold higher than that of standard antiseizure medications. Conclusion. Timely initiation of rational therapy in IESS is the result of passing through several consecutive threshold stages of the patient care pathway. The key systemic barriers in Saint Petersburg are late recognition of epileptic spasms and insufficient implementation of first-line therapy. These findings highlight the necessity of analyzing patient pathways within specific healthcare models and developing targeted programs for early detection and optimization of initial treatment.
- 30 April 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (1)
Open AccessThreshold analysis of the patient’s route in infantile epileptic spasms syndrome: from the onset of spasms to first-line therapy
Background. Infantile epileptic spasms syndrome (IESS) is one of the most severe forms of early-onset epileptic encephalopathies and is associated with a high risk of pharmacoresistance, severe cognitive impairment, and premature mortality. Disease prognosis critically depends on the timeliness and adequacy of first-line therapy. Although delayed treatment of IESS is a universal problem, the specific stages of the patient care pathway at which delays occur may vary substantially depending on the organization of healthcare delivery. Aim. To identify key threshold stages of the patient care pathway and major barriers to timely initiation of rational therapy in children with IESS within the healthcare system of Saint Petersburg. Materials and methods. A retrospective observational study was conducted using the archive of the Epilepsy Clinic since 2018. A total of 130 children diagnosed with IESS according to International League Against Epilepsy criteria were included. Clinical and anamnestic data, magnetic resonance imaging findings, electroencephalography/video-electroencephalography monitoring results, and genetic testing data were analyzed. A threshold analysis of six consecutive stages of the patient care pathway was performed, from initial recognition of spasms to prescription of appropriate first-line therapy regimens. Early treatment response was assessed 2 weeks after therapy initiation Results. Developmental abnormalities prior to epileptic spasms onset were identified in 78 % of children; potentially epileptogenic magnetic resonance imaging abnormalities were found in 67 %. Causative genetic variants were detected in 18 % of the entire cohort. In 39 % of patients, the diagnosis was not established within the first month after spasm onset. In 96 (74 %) of 130 children, rational therapy was initiated more than one month after spasm onset. Six threshold points of potential treatment delay were identified. The main point of patient loss was late recognition of spasms at the stage of initial medical contact (loss of 27 out of 130 children). Moreover, delay at this stage deprived the child of any chance to receive timely therapy and constituted an insurmountable barrier to the subsequent steps of care. The second most important barrier was failure to initiate appropriate first-line therapy at treatment onset. The effectiveness of first-line therapy was more than 12-fold higher than that of standard antiseizure medications. Conclusion. Timely initiation of rational therapy in IESS is the result of passing through several consecutive threshold stages of the patient care pathway. The key systemic barriers in Saint Petersburg are late recognition of epileptic spasms and insufficient implementation of first-line therapy. These findings highlight the necessity of analyzing patient pathways within specific healthcare models and developing targeted programs for early detection and optimization of initial treatment.
- Open Access
- 12 January 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 20 (4) , 84-92
New arguments for patients with apnea and epilepsy
The impetus for writing this article was the recent publication in The Lancet (October 2025) of the results of a multicenter, randomized, double-blind, placebo-controlled trial of sultiame, a well-known antiepileptic drug, in patients with obstructive sleep apnea without epilepsy. This article analyzes the role of apnea in epilepsy, issues of diagnostics and therapy are considered. Key findings: apnea is a common, underestimated comorbidity of epilepsy, worsening the course of the underlying disease, and is a trigger for sudden unexpected death in epilepsy. Patients with epilepsy should be assessed for the risk of developing ictal apnea and screened for obstructive sleep apnea to ensure timely detection and treatment. A number of antiepileptic drugs (benzodiazepines, valproates) can cause or exacerbate apnea. Based on the high-quality evidence obtained, sultiame should be considered as a first-line antiepileptic drug in patients with epilepsy and apnea.
- 12 January 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 20 (4) , 84-92
Open AccessNew arguments for patients with apnea and epilepsy
The impetus for writing this article was the recent publication in The Lancet (October 2025) of the results of a multicenter, randomized, double-blind, placebo-controlled trial of sultiame, a well-known antiepileptic drug, in patients with obstructive sleep apnea without epilepsy. This article analyzes the role of apnea in epilepsy, issues of diagnostics and therapy are considered. Key findings: apnea is a common, underestimated comorbidity of epilepsy, worsening the course of the underlying disease, and is a trigger for sudden unexpected death in epilepsy. Patients with epilepsy should be assessed for the risk of developing ictal apnea and screened for obstructive sleep apnea to ensure timely detection and treatment. A number of antiepileptic drugs (benzodiazepines, valproates) can cause or exacerbate apnea. Based on the high-quality evidence obtained, sultiame should be considered as a first-line antiepileptic drug in patients with epilepsy and apnea.
- Open Access
- 19 December 2025
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 20 (3) , 41-54
Epilepsy and attention-deficit/hyperactivity disorder. Problems of antiepileptic therapy
This review is based on the consensus statement of the International League Against Epilepsy’s pediatric panel on the diagnosis and management of patients with epilepsy and attention-deficit/hyperactivity disorder (ADHD). The document has been expanded and supplemented by later publications. Its main provisions: ADHD is 3–5 times more common in children with epilepsy than in the general population; the risk of developing epilepsy in people with ADHD is also increased. No gender differences were found in the manifestations of ADHD in boys and girls with epilepsy. Taking valproate during pregnancy increases the risk of developing ADHD in the child. The presence of intellectual and developmental disabilities, as well as poor seizure control, increase the risk of developing ADHD. Screening for ADHD should be performed in all children with epilepsy, beginning at age 6, when the diagnosis of epilepsy is established. Children should be retested annually for ADHD symptoms, including after a change in antiepileptic medication. The International League Against Epilepsy recommends the Strengths and Difficulties Questionnaire for ADHD screening. Behavioral problems occur more frequently with polytherapy than with monotherapy. A number of antiepileptic drugs (for example, valproate, benzodiazepines, etc.) can worsen cognitive and behavioral problems in patients with epilepsy and ADHD. Sulthiame has good cognitive tolerability and is approved for the treatment of hyperkinetic behavior and behavioral disorders in epilepsy, making it the drug of choice for patients with epilepsy and behavioral disorders, such as ADHD.
- 19 December 2025
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 20 (3) , 41-54
Open AccessEpilepsy and attention-deficit/hyperactivity disorder. Problems of antiepileptic therapy
This review is based on the consensus statement of the International League Against Epilepsy’s pediatric panel on the diagnosis and management of patients with epilepsy and attention-deficit/hyperactivity disorder (ADHD). The document has been expanded and supplemented by later publications. Its main provisions: ADHD is 3–5 times more common in children with epilepsy than in the general population; the risk of developing epilepsy in people with ADHD is also increased. No gender differences were found in the manifestations of ADHD in boys and girls with epilepsy. Taking valproate during pregnancy increases the risk of developing ADHD in the child. The presence of intellectual and developmental disabilities, as well as poor seizure control, increase the risk of developing ADHD. Screening for ADHD should be performed in all children with epilepsy, beginning at age 6, when the diagnosis of epilepsy is established. Children should be retested annually for ADHD symptoms, including after a change in antiepileptic medication. The International League Against Epilepsy recommends the Strengths and Difficulties Questionnaire for ADHD screening. Behavioral problems occur more frequently with polytherapy than with monotherapy. A number of antiepileptic drugs (for example, valproate, benzodiazepines, etc.) can worsen cognitive and behavioral problems in patients with epilepsy and ADHD. Sulthiame has good cognitive tolerability and is approved for the treatment of hyperkinetic behavior and behavioral disorders in epilepsy, making it the drug of choice for patients with epilepsy and behavioral disorders, such as ADHD.
- Open Access
- 30 June 2025
- Published by National Association of Neurologists in NATIONAL JOURNAL OF NEUROLOGY
- Vol. 1 (27) , 18-25
The Close Relationship Between Apnea, Epilepsy and SUDEP
A review of recent publications about sleep apnea and epilepsy has been shown that the respiratory system plays a crucial role in the development of sudden unexpected death in epilepsy (SUDEP). Sleep apnea can provoke or worsen epilepsy, and treatment of sleep apnea can reduce the number of seizures. The International Antiepileptic League identifies a special group of sleep-related epilepsies (sleep-accentuated epilepsies; sleep-associated epilepsies; epilepsy of awakening), among which, first of all, apnea screening should be carried out. In patients with apnea and epilepsy, the use of medications and therapies that cause or exacerbate apnea attacks should be limited. Apnea therapy should be used in a comprehensive and individualized way, in particular, treatment of obesity, CPAP therapy, sultiam (from 200 mg/day for adult patients with apnea and epilepsy), treatment of ENT pathology, etc. are recommended.
- 30 June 2025
- Published by National Association of Neurologists in NATIONAL JOURNAL OF NEUROLOGY
- Vol. 1 (27) , 18-25
Open AccessThe Close Relationship Between Apnea, Epilepsy and SUDEP
A review of recent publications about sleep apnea and epilepsy has been shown that the respiratory system plays a crucial role in the development of sudden unexpected death in epilepsy (SUDEP). Sleep apnea can provoke or worsen epilepsy, and treatment of sleep apnea can reduce the number of seizures. The International Antiepileptic League identifies a special group of sleep-related epilepsies (sleep-accentuated epilepsies; sleep-associated epilepsies; epilepsy of awakening), among which, first of all, apnea screening should be carried out. In patients with apnea and epilepsy, the use of medications and therapies that cause or exacerbate apnea attacks should be limited. Apnea therapy should be used in a comprehensive and individualized way, in particular, treatment of obesity, CPAP therapy, sultiam (from 200 mg/day for adult patients with apnea and epilepsy), treatment of ENT pathology, etc. are recommended.
- Open Access
- 15 January 2024
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 19 (1) , 25‑40
Efficacy and tolerability of sulthiame in the treatment of epilepsy: a literature review
This review aims to summarize the available evidence on the efficacy and tolerability of sulthiame for different forms of epilepsy. The analysis of international publications suggests that sulthiame is considered as a first-line drug for the treatment of age-dependent epilepsy with central temporal spikes (rolandic epilepsy). Sulthiame is highly effective in children with epileptic encephalopathies manifesting with spike-and-wave activity during sleep, including Landau-Kleffner syndrome, as well as in patients with myoclonic seizures. The drug might be also effective in patients with other forms of focal epilepsy, including those resistant to therapy. The tolerability of sulthiame is higher that that of old antiepileptic drugs and even levetiracetam; thus, it is associated with a lower risk of treatment interruptions due to adverse events. Moreover, sulthiame can be used for behavioral disorders (such as hyperkinetic behavior, aggressiveness) and cognitive impairments. Sulthiame can be effective in patients with epilepsy and sleep apnea.
- 15 January 2024
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 19 (1) , 25‑40
Open AccessEfficacy and tolerability of sulthiame in the treatment of epilepsy: a literature review
This review aims to summarize the available evidence on the efficacy and tolerability of sulthiame for different forms of epilepsy. The analysis of international publications suggests that sulthiame is considered as a first-line drug for the treatment of age-dependent epilepsy with central temporal spikes (rolandic epilepsy). Sulthiame is highly effective in children with epileptic encephalopathies manifesting with spike-and-wave activity during sleep, including Landau-Kleffner syndrome, as well as in patients with myoclonic seizures. The drug might be also effective in patients with other forms of focal epilepsy, including those resistant to therapy. The tolerability of sulthiame is higher that that of old antiepileptic drugs and even levetiracetam; thus, it is associated with a lower risk of treatment interruptions due to adverse events. Moreover, sulthiame can be used for behavioral disorders (such as hyperkinetic behavior, aggressiveness) and cognitive impairments. Sulthiame can be effective in patients with epilepsy and sleep apnea.